Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.
Combination nab-paclitaxel and pembrolizumab demonstrated activity in platinum-refractory or cisplatin-ineligible advanced urothelial cancer.
Chemoresection with mitomycin reduces the number of required surgical procedures in recurrent nonmuscle invasive bladder cancer, a study suggests.
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Of 19 patients with high-risk NMIBC treated with local docetaxel, 14 had prior BCG exposure.
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.
Adding tislelizumab to gemcitabine/cisplatin improved outcomes in patients with locally advanced or metastatic bladder cancer.
Investigators hypothesize that patients presented later to their health care providers during the first year of the pandemic.
The prevalence of metastatic cancers in the US has risen in recent years and will increase further by 2025, according to researchers.
The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.
Gemcitabine plus docetaxel is safe and effective in BCG-naive high-risk non-muscle-invasive bladder cancer, according to researchers.
A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma than among matched control individuals, a study showed.
Men tend to have a higher risk of cancer than women, and factors such as smoking, alcohol use, and diet do not appear to explain this disparity.
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Patients treated with radiotherapy had a greater risk of second primary cancer when compared with patients who underwent surgery or surveillance.
The biologics license application for Vicineum included preliminary findings from the phase 3 VISTA trial.
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Adding olaparib to durvalumab did not improve progression-free or overall survival.